^
7ms
12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi (clinicaltrials.gov)
P2, N=0, Withdrawn, Albert Chiou | N=12 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
NFX-179
1year
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
P2, N=199, Completed, NFlection Therapeutics, Inc. | Active, not recruiting --> Completed
Trial completion
|
NF1 (Neurofibromin 1)
|
NFX-179
almost2years
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
P2, N=199, Active, not recruiting, NFlection Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Jan 2023 --> Sep 2023
Enrollment closed • Trial completion date • Trial primary completion date
|
NF1 (Neurofibromin 1)
|
NFX-179
3years
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
P2, N=168, Recruiting, NFlection Therapeutics, Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
NF1 (Neurofibromin 1)
|
NFX-179
over3years
Clinical • New P2 trial
|
NF1 (Neurofibromin 1)
|
NFX-179
over3years
Trial completion
|
NF1 (Neurofibromin 1)
|
NFX-179